semaglutide ckd trial Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with experience more stable kidney function compared with placebo In the FLOW trial, researchers

IGF-1 DES is a truncated version (des(1-3)IGF-1) that has higher potency at the receptor (~5-10x) but a very short half-life (~2030 minutes)

J ASEAN Federation Endocr Soc

The authors themselves described it as a small preliminary study.[15] A 2025 pilot report described intravenous administration to two healthy adults at doses up to 20 mg, with no measurable changes in cardiac, hepatic, renal or thyroid biomarkers and no reported adverse effects.[16] Two individuals cannot characterise uncommon reactions, immunogenicity, long-term toxicity, reproductive safety or oncological risk

Although the primary outcome was cardiotoxicity rather than metabolic disease, which limits its relevance to obesity or insulin resistance, this study provided insights into the effect pathways along which Akkermansia acts

51:19 (2024) Kobayashi J, Sasaki D, Hara KY, Hasunuma T, Kondo A